JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model. 了解更多

JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively. 了解更多

JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. 了解更多

JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1. 了解更多

JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. 了解更多

JAK Inhibitor I 是JAK1、JAK2和JAK3的一种高效、可逆、细胞通透性和ATP竞争性抑制剂。 了解更多

Gusacitinib (ASN-002) is a potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. 了解更多

Delgocitinib is a novel and specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. 了解更多

Oclacitinib maleate (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting JAK1 (IC50=10 nM). 了解更多

PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. 了解更多

Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM. IC50 & Target: IC50: 43 nM (JAK1), 200 nM (JAK2) 了解更多

Ruxolitinib Phosphate是ruxolitinib的磷酸盐形式，ruxolitinib是一种口服生物可利用的Janus相关激酶(JAK)抑制剂，具有潜在的抗肿瘤和免疫调节活性。 了解更多

PRT 062070 (Cerdulatinib)是一种新型的口服双脾酪氨酸激酶（Syk）和janus激酶（JAK）抑制剂。Cerdulatinib优先抑制各种细胞类型中JAK1和JAK3依赖性细胞因子介导的信号传导和功能性反应。 了解更多

Ganoderic acid A can inhibit of the JAK-STAT3 signaling pathway, also inhibit proliferation, viability, ROS. 了解更多

NVP-BSK805 dihydrochloride (BSK805 dihydrochloride) is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively. 了解更多

JAK3-IN-2 is a potent and highly selective JAK3 inhibitor with IC50 of 0.15 nM. dispalys >4,300-fold selectivity over JAK1, JAK2 and TYK2, and other kinases BMX, EGFR, ITK and BTK; blocks cytokine signaling through JAK3, but not through other JAK family enzymes; inhibits IL-7 induced pSTAT5 in CD3+, CD8+ T cells with IC50 of 280 nM; sufficiently blocks the development of inflammation in a rat model of rheumatoid arthritis, while sparing hematopoiesis. 了解更多

Peficitinib (ASP015K,JNJ-54781532)是一种新型的强力JAK抑制剂，在佐剂诱导的大鼠关节炎模型中显示出强效功效。 了解更多

Baricitinib phosphate是一种选择性的JAK1和JAK2抑制剂，IC50为5.9 nM和5.7 nM，选择性是JAK3和Tyk2的?70和?10倍，对c-Met和Chk2没有抑制作用。 了解更多

ZM 449829是有效的、选择性的JAK3抑制剂（Janus酪氨酸激酶3），与JAK3 ATP位点竞争性结合。 了解更多

CYT387 sulfate salt是JAK1/JAK2的ATP竞争性抑制剂，IC50为11 nM/18 nM，是JAK3的约10倍选择性。 了解更多

S-Ruxolitinib是INCB018424的手性化合物，是一种有效且选择性的小分子Janus激酶1（JAK1）和JAK2抑制剂。 了解更多

Filgotinib是一种选择性的JAK1抑制剂，对于JAK1，JAK2，JAK3和TYK2的IC50分别为10 nM，28 nM，810 nM和116 nM。 了解更多

XL019是janus相关激酶2 (JAK-2)的生物可利用抑制剂，具有潜在的抗肿瘤活性。 了解更多

BMS-911543是一种有效的、选择性JAK2小分子抑制剂。 了解更多

WP1066是一种新型的JAK2抑制剂，可抑制携带JAK2 V617F突变的类人甲状腺细胞增殖并诱导其凋亡。 了解更多

Baricitinib，也称为INCB028050或LY3009104，是一种选择性口服可生物利用的JAK1/JAK2抑制剂，对JAK1（5.9 nM）和JAK2（5.7 nM）具有纳摩尔浓度。 了解更多

NVP-BSK805是喹喔啉JAK2抑制剂对红细胞增多症的有效和选择性抑制，喹喔啉JAK2抑制剂可有效抑制小鼠和大鼠中重组人促红细胞生成素诱导的红细胞增多症和髓外红细胞生成。IC50为0.5 nM，比作用于JAK1， JAK3和TYK2选择性高20倍以上。 了解更多

Cyt387 (Momelotinib)是Janus激酶JAK1和JAK2的抑制剂，可作为ATP竞争者，IC50值分别为11和18 nM。 了解更多

CP-690550 (Tofacitinib citrate)是口服的高选择性Janus激酶（JAK）酶抑制剂。 了解更多

LY2784544被鉴定为对JAK2-V617F具有高度选择性，并已进入人类临床试验，用于治疗几种骨髓增生性疾病。 了解更多

AT9283抑制极光激酶A和B，并靶向与骨髓细胞增殖相关的其他酪氨酸和丝氨酸/苏氨酸激酶。 了解更多

AZD1480是一种新型有效的小型JAK2抑制剂，IC50为0.26 nM。 了解更多

GDC046 (Compound 3) is a potent, selective, and orally bioavailable inhibitor of TYK2 with Ki of 4.8 nM, 83.8 nM, 27.6 nM and 253 nM for TYK2, JAK1, JAK2, and JAK3, respectively. 了解更多

BD750, an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC50 values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively. 了解更多

TG-89 is an inhibitor of JAK2 with IC50 of 11.2 μM. 了解更多

JAK3-IN-1 is a potent JAK3 inhibitor with IC50 of 4.8 nM, also inhibits JAK1 (IC50 = 896 nM) and JAK2 (IC50 = 1050 nM). 了解更多

SAR-20347 is an inhibitor of TYK2, JAK1, JAK2 and JAK3 with IC50s of 0.6, 23, 26 and 41 nM, respectively. 了解更多

JAK2 JH2 Tracer is a fluorescent probe for the JAK2 JH2 domain, with Kd of 0.2 μM. 了解更多

JAK1-IN-3 is a selective JAK1 inhibitor, with an IC50 of 73 nM, weakly inhibits JAK2, and shows little inhibition on JAK3 (IC50, >14.7, >30 μM, respectively). 了解更多

AZ-3 is a potent and selective JAK1 inhibitor with an IC50 of 34 nM. 了解更多

Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3. 了解更多

PF-06700841 P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. 了解更多

JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively. 了解更多

Lestaurtinib (CEP-701;KT-5555) is a multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits JAK2, FLT3 and TrkA with IC50s of 0.9, 3 and less than 25 nM, respectively. 了解更多

Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3. 了解更多

Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively. 了解更多

JAK1-IN-4 is a potent and selective JAK1 inhibitor, with IC50s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM). 了解更多

JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. 了解更多

JAK1-IN-7 is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect. 了解更多